First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis

Lignende værker

• Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study
  af: Naganuma, Makoto, et al.
  Udgivet: (2017)
• Effects of vedolizumab in Japanese patients with Crohn’s disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses
  af: Watanabe, Kenji, et al.
  Udgivet: (2019)
• Adrenomedullin for steroid-resistant ulcerative colitis: a randomized, double-blind, placebo-controlled phase-2a clinical trial
  af: Kita, Toshihiro, et al.
  Udgivet: (2020)
• Infliximab for pediatric patients with ulcerative colitis: a phase 3, open-label, uncontrolled, multicenter trial in Japan
  af: Hitoshi Tajiri, et al.
  Udgivet: (2019-10-01)
• Infliximab for pediatric patients with ulcerative colitis: a phase 3, open-label, uncontrolled, multicenter trial in Japan
  af: Tajiri, Hitoshi, et al.
  Udgivet: (2019)